Welcome to PATH

Path MembersThe Programs for Assessment of Technology in Health (PATH) Research Institute consists of multiple research programs in economic evaluation and health technology assessment (HTA).  PATH's educational and research activities are separated into 4 primary programs:  the Field Evaluation and Economic Assessment Program (FEEAP); the Health Technology Assessment Program (HTAP); the Trial and Economic Modelling Methodology Program (TEMMP); and the Health Technology Assessment Educational Learning Program (HELP). The PATH Research Institute is affiliated with the Centre for the Evaluation of Medicines (CEM) at St. Joseph's Healthcare Hamilton and the Department of Clinical Epidemiology and Biostatistics at McMaster University.

Recent News

Recent Reports

  • Chandra K, Goeree R, Blackhouse G, Bornstein M, McMartin K, Bradley N, Franek J, Kaulback K, Taylor C. Diabetes strategy evidence platform: a summary of evidence-based analyses. Ontario Health Technology Assessment Series 2009;9(19). pdf
  • Chandra K, Goeree R, Blackhouse G, O'Reilly D, Bornstein M, McMartin K, Bradley N, Franek J, Kaulback K, Taylor C. Application of the Ontario Diabetes Economic Model (ODEM) to determine the cost-effectiveness and budget impact of selected type 2 diabetes interventions in Ontario. Ontario Health Technology Assessment Series 2009;9(25). pdf
  • Assasi N, Blackhouse G, Xie F, Gaebel K, Marshall J, Irvine EJ, Giacomini M, Robertson D, Campbell K, Hopkins R, Goeree R. Overview of anti-TNF-α drugs for refractory inflammatory bowel disease [Technology overview no 52]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009. pdf
  2. 1
  3. 2
  4. 3
  5. 4
  6. Next page

Recent Presentations

  • Goeree R, Lim ME, Hopkins R, et al. Using population-based estimates for disease modelling: Potential bias compared to using disease-specific death and complication risk estimates. ISPOR 12th Annual European Congress, Paris, France. October 24-27, 2009 (Oral presentation).
  • Bischof M, Lim M, Ferrusi I, et al. R there any differences between Excel and R? Comparison of ICER estimates and CEACS obtained from a model implemented in Microsoft Excel and R. ISPOR 12th Annual European Congress, Paris, France. October 24-27, 2009 (Oral presentation).
  • Blackhouse G, Xie F, Gaebel K, Robertson D, Levine M, Chalk C, Assasi N, Goeree RA. Cost-utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. ISPOR 12th Annual European Congress, Paris France, October 24-27, 2009 (Poster).
  2. 1
  3. 2
  4. 3
  5. 4
  6. Next page

Recent Publications

  • Oremus M, Tarride JE.  An economic evaluation of surgery versus collagen injection for the treatment of female stress urinary incontinence.  Canadian Journal of Urology (Forthcoming, 2010).
  • Pullenayegum E, Tarride JE, Xie F, Gerstein H, Goeree R, O’Reilly D.  Analysis of health utility data when some subjects attain the upper bound of 1: Are TOBIT and CLAD models appropriate?  Value in Health (Forthcoming, 2010).
  • Hopkins RB, Goeree R, Longo CJ. Estimating the national wage loss from cancer in Canada.  Current Oncology (Forthcoming, 2010).
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. 6
  8. Next page